New combo therapy shows promise in advanced cancer trial
Disease control
Completed
This early-stage study tested a new treatment called VE800 combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goal was to see if the combination is safe and whether it can shrink …
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 03:24 UTC